Achieve Clinical Data Transparency with the 4 Cs of Collaboration Blog Post
In this blog, we look at how you can enhance clinical data transparency and make data informed decisions with the 4 Cs of collaboration.
Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region Blog Post
Abstract The integration of MID3 offers a transformative opportunity for the MENA region to advance pharmaceutical research and healthcare through sophisticated quantitative models like population PK/PD and PBPK modeling. Educational...
Simcyp™ In Vitro Data Analysis (SIVA) Toolkit Blog Post
Download PDF
Unlock Global Regulatory Success: Overcoming Early Drug Development Challenges [APAC Webinar] Blog Post
Summary Navigating early drug development is critical to ensuring the long-term success of therapeutic candidates. This webinar explores key strategies to overcome common challenges, with expert insights from APAC and...
Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters Blog Post
Rajesh Krishna, PhD January 10, 2025 Friedreich’s Ataxia (FA) is a rare, genetic, and progressive neurodegenerative disorder. A defect in the Frataxin (FXN) gene causes FA. FXN is essential for...
Certara Appoints New Head of Biometrics, Data Science, and Access Blog Post
January 10, 2025 RADNOR, PA. – January 10, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Tiffany Woodworth as Head of Biometrics, Data...
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA) Blog Post
Summary In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive Models," Matt Zierhut shares insights on using clinical trial and real-world data. You'll learn...
